Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy Planning, Computer-Assisted | 120 | 2024 | 1679 | 11.320 |
Why?
|
Radiotherapy, Intensity-Modulated | 36 | 2024 | 798 | 5.540 |
Why?
|
Radiotherapy Dosage | 98 | 2024 | 2916 | 3.710 |
Why?
|
Radiotherapy, Conformal | 31 | 2011 | 549 | 3.690 |
Why?
|
Radiometry | 29 | 2013 | 817 | 3.230 |
Why?
|
Radiation Oncology | 12 | 2024 | 572 | 2.590 |
Why?
|
Radiotherapy | 17 | 2023 | 1502 | 1.910 |
Why?
|
Algorithms | 61 | 2024 | 14164 | 1.830 |
Why?
|
Phantoms, Imaging | 35 | 2024 | 2512 | 1.770 |
Why?
|
Health Physics | 5 | 2024 | 37 | 1.510 |
Why?
|
Protons | 17 | 2024 | 1113 | 1.390 |
Why?
|
Radiation Pneumonitis | 2 | 2022 | 100 | 1.330 |
Why?
|
Radiotherapy, Computer-Assisted | 8 | 2011 | 90 | 1.270 |
Why?
|
Radiotherapy, High-Energy | 11 | 2009 | 228 | 1.200 |
Why?
|
Brain Neoplasms | 14 | 2024 | 9118 | 1.130 |
Why?
|
Neoplasms | 29 | 2023 | 22371 | 1.120 |
Why?
|
Models, Biological | 21 | 2019 | 9497 | 0.930 |
Why?
|
Models, Theoretical | 18 | 2021 | 3573 | 0.910 |
Why?
|
Radiation Injuries | 7 | 2024 | 1198 | 0.900 |
Why?
|
Positron-Emission Tomography | 17 | 2020 | 6669 | 0.880 |
Why?
|
Scattering, Radiation | 14 | 2016 | 489 | 0.880 |
Why?
|
Photons | 18 | 2018 | 594 | 0.850 |
Why?
|
Chordoma | 5 | 2023 | 349 | 0.850 |
Why?
|
Motion | 10 | 2012 | 790 | 0.830 |
Why?
|
Salaries and Fringe Benefits | 1 | 2024 | 263 | 0.790 |
Why?
|
Muscle Fibers, Skeletal | 2 | 2024 | 553 | 0.760 |
Why?
|
Liver Neoplasms | 8 | 2021 | 4363 | 0.760 |
Why?
|
Monte Carlo Method | 20 | 2024 | 1259 | 0.730 |
Why?
|
Organs at Risk | 5 | 2022 | 367 | 0.710 |
Why?
|
Uncertainty | 8 | 2022 | 769 | 0.710 |
Why?
|
Four-Dimensional Computed Tomography | 2 | 2011 | 142 | 0.670 |
Why?
|
Lung Neoplasms | 18 | 2024 | 13586 | 0.670 |
Why?
|
Glioblastoma | 4 | 2023 | 3464 | 0.650 |
Why?
|
Diffusion Tensor Imaging | 3 | 2024 | 2420 | 0.640 |
Why?
|
Physics | 5 | 2021 | 92 | 0.610 |
Why?
|
Tomography, X-Ray Computed | 27 | 2024 | 20762 | 0.570 |
Why?
|
Tumor Burden | 4 | 2022 | 1906 | 0.550 |
Why?
|
Head and Neck Neoplasms | 16 | 2024 | 2931 | 0.550 |
Why?
|
Glioma | 3 | 2024 | 3503 | 0.550 |
Why?
|
Radiation Dosage | 7 | 2018 | 1967 | 0.540 |
Why?
|
Spinal Neoplasms | 6 | 2013 | 715 | 0.500 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2024 | 5432 | 0.500 |
Why?
|
Movement | 10 | 2015 | 1490 | 0.500 |
Why?
|
Probability | 8 | 2022 | 2479 | 0.490 |
Why?
|
Dose-Response Relationship, Radiation | 13 | 2011 | 876 | 0.480 |
Why?
|
Technology, Radiologic | 4 | 2013 | 160 | 0.480 |
Why?
|
Humans | 154 | 2024 | 768171 | 0.450 |
Why?
|
Particle Accelerators | 10 | 2021 | 173 | 0.430 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2024 | 3390 | 0.430 |
Why?
|
Lung Injury | 1 | 2018 | 433 | 0.420 |
Why?
|
Computer Simulation | 14 | 2012 | 6283 | 0.390 |
Why?
|
Reproducibility of Results | 28 | 2024 | 20225 | 0.380 |
Why?
|
Image Processing, Computer-Assisted | 16 | 2024 | 9016 | 0.380 |
Why?
|
Mathematics | 6 | 2019 | 704 | 0.380 |
Why?
|
Gadolinium DTPA | 1 | 2014 | 823 | 0.370 |
Why?
|
Biomedical Technology | 1 | 2013 | 210 | 0.360 |
Why?
|
Software | 8 | 2012 | 4480 | 0.340 |
Why?
|
Sensitivity and Specificity | 19 | 2024 | 14729 | 0.340 |
Why?
|
Relative Biological Effectiveness | 10 | 2018 | 313 | 0.330 |
Why?
|
Diffusion of Innovation | 1 | 2013 | 724 | 0.310 |
Why?
|
Database Management Systems | 1 | 2009 | 263 | 0.290 |
Why?
|
Hepatocytes | 1 | 2014 | 1247 | 0.280 |
Why?
|
Prostatic Neoplasms | 16 | 2022 | 11101 | 0.280 |
Why?
|
Biophysical Phenomena | 9 | 2003 | 320 | 0.280 |
Why?
|
Body Burden | 8 | 2009 | 158 | 0.270 |
Why?
|
Quality Assurance, Health Care | 2 | 2016 | 2176 | 0.270 |
Why?
|
Models, Statistical | 13 | 2022 | 5107 | 0.270 |
Why?
|
Biophysics | 9 | 2003 | 379 | 0.270 |
Why?
|
Electrons | 3 | 2008 | 264 | 0.270 |
Why?
|
Therapy, Computer-Assisted | 1 | 2008 | 265 | 0.260 |
Why?
|
Synchrotrons | 3 | 2017 | 40 | 0.260 |
Why?
|
Cerebellar Neoplasms | 1 | 2010 | 591 | 0.240 |
Why?
|
Respiratory Mechanics | 2 | 2008 | 721 | 0.240 |
Why?
|
Respiration | 6 | 2010 | 1665 | 0.240 |
Why?
|
Medulloblastoma | 1 | 2010 | 683 | 0.240 |
Why?
|
Visible Human Projects | 1 | 2024 | 12 | 0.240 |
Why?
|
Calibration | 6 | 2023 | 819 | 0.230 |
Why?
|
Normal Distribution | 5 | 2012 | 272 | 0.220 |
Why?
|
Spine | 1 | 2010 | 1140 | 0.210 |
Why?
|
Pancreatic Neoplasms | 3 | 2011 | 5442 | 0.210 |
Why?
|
Linear Models | 2 | 2018 | 5884 | 0.200 |
Why?
|
Linear Energy Transfer | 1 | 2003 | 154 | 0.200 |
Why?
|
Career Mobility | 1 | 2024 | 262 | 0.200 |
Why?
|
Sarcoma | 2 | 2022 | 1806 | 0.200 |
Why?
|
Technology Assessment, Biomedical | 1 | 2004 | 312 | 0.190 |
Why?
|
Head | 3 | 2024 | 926 | 0.190 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2055 | 0.190 |
Why?
|
Job Satisfaction | 1 | 2024 | 548 | 0.180 |
Why?
|
Feasibility Studies | 7 | 2022 | 5315 | 0.180 |
Why?
|
Anisotropy | 1 | 2024 | 1292 | 0.170 |
Why?
|
Time Factors | 15 | 2018 | 40220 | 0.170 |
Why?
|
Prostheses and Implants | 1 | 2007 | 1277 | 0.170 |
Why?
|
Bone Marrow | 1 | 2010 | 2935 | 0.170 |
Why?
|
X-Ray Therapy | 1 | 1999 | 8 | 0.160 |
Why?
|
Skull Neoplasms | 2 | 2013 | 173 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 10 | 2023 | 36741 | 0.160 |
Why?
|
Entrepreneurship | 1 | 2019 | 23 | 0.160 |
Why?
|
Spectrometry, Gamma | 1 | 2018 | 5 | 0.160 |
Why?
|
Lymphocyte Count | 1 | 2021 | 794 | 0.160 |
Why?
|
Gamma Rays | 2 | 2024 | 319 | 0.150 |
Why?
|
Muscles | 1 | 2023 | 1582 | 0.150 |
Why?
|
Radiobiology | 1 | 2018 | 89 | 0.150 |
Why?
|
Skull Base Neoplasms | 1 | 2021 | 279 | 0.150 |
Why?
|
Radiation Protection | 4 | 2013 | 428 | 0.140 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2004 | 1232 | 0.140 |
Why?
|
Databases, Factual | 2 | 2009 | 8080 | 0.130 |
Why?
|
Subtraction Technique | 3 | 2009 | 517 | 0.130 |
Why?
|
Organizational Innovation | 1 | 2019 | 540 | 0.130 |
Why?
|
Patient Positioning | 2 | 2015 | 332 | 0.130 |
Why?
|
Oxygen Radioisotopes | 1 | 2015 | 75 | 0.120 |
Why?
|
Markov Chains | 1 | 2019 | 979 | 0.120 |
Why?
|
Bayes Theorem | 1 | 2022 | 2359 | 0.110 |
Why?
|
Rotation | 2 | 2010 | 517 | 0.110 |
Why?
|
Academic Medical Centers | 1 | 2024 | 2785 | 0.110 |
Why?
|
Radiosurgery | 4 | 2015 | 1330 | 0.110 |
Why?
|
Radiation Tolerance | 3 | 2014 | 476 | 0.110 |
Why?
|
Image Enhancement | 1 | 2024 | 2880 | 0.110 |
Why?
|
Scintillation Counting | 1 | 2013 | 36 | 0.110 |
Why?
|
Patient Care Planning | 1 | 1999 | 905 | 0.110 |
Why?
|
Equipment Design | 4 | 2013 | 3522 | 0.110 |
Why?
|
Retrospective Studies | 7 | 2022 | 81760 | 0.110 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 427 | 0.100 |
Why?
|
Cholangiocarcinoma | 1 | 2018 | 561 | 0.100 |
Why?
|
Stereotaxic Techniques | 5 | 2002 | 553 | 0.100 |
Why?
|
Quality Control | 3 | 2006 | 836 | 0.100 |
Why?
|
Artifacts | 3 | 2007 | 1926 | 0.100 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2016 | 459 | 0.100 |
Why?
|
Male | 32 | 2024 | 364731 | 0.100 |
Why?
|
X-Rays | 3 | 2002 | 311 | 0.100 |
Why?
|
Models, Organizational | 1 | 2015 | 548 | 0.090 |
Why?
|
Forecasting | 3 | 2013 | 2945 | 0.090 |
Why?
|
Hospitals, General | 1 | 2015 | 809 | 0.090 |
Why?
|
Risk | 1 | 2023 | 9613 | 0.090 |
Why?
|
Chondrosarcoma | 1 | 2013 | 306 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2016 | 1443 | 0.090 |
Why?
|
Rectum | 5 | 2007 | 900 | 0.090 |
Why?
|
Esophagus | 1 | 2016 | 1042 | 0.080 |
Why?
|
Swine | 3 | 2024 | 5997 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9419 | 0.080 |
Why?
|
Cyclotrons | 1 | 2008 | 30 | 0.080 |
Why?
|
Attitude | 1 | 2013 | 772 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1436 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3786 | 0.070 |
Why?
|
Thigh | 2 | 2022 | 239 | 0.070 |
Why?
|
Stochastic Processes | 1 | 2009 | 360 | 0.070 |
Why?
|
Medical Informatics | 1 | 2015 | 743 | 0.070 |
Why?
|
Carbon Isotopes | 1 | 2008 | 458 | 0.070 |
Why?
|
Water | 4 | 2022 | 1421 | 0.070 |
Why?
|
Hemangiopericytoma | 1 | 2007 | 71 | 0.070 |
Why?
|
Lung | 6 | 2024 | 10101 | 0.070 |
Why?
|
Fourier Analysis | 1 | 2008 | 439 | 0.070 |
Why?
|
Eye Neoplasms | 3 | 2011 | 306 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2001 | 3533 | 0.070 |
Why?
|
Plastics | 1 | 2007 | 119 | 0.070 |
Why?
|
Information Dissemination | 1 | 2015 | 1143 | 0.070 |
Why?
|
Research | 1 | 2015 | 1979 | 0.070 |
Why?
|
Risk Assessment | 3 | 2017 | 24318 | 0.070 |
Why?
|
Tomography | 1 | 2008 | 442 | 0.070 |
Why?
|
Insurance Coverage | 1 | 2017 | 1946 | 0.060 |
Why?
|
Computing Methodologies | 1 | 2005 | 17 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2018 | 2334 | 0.060 |
Why?
|
Filtration | 1 | 2006 | 229 | 0.060 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2011 | 290 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2517 | 0.060 |
Why?
|
Mediastinal Neoplasms | 2 | 1999 | 403 | 0.060 |
Why?
|
Ependymoma | 1 | 2008 | 328 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2007 | 1791 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2017 | 3620 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5536 | 0.060 |
Why?
|
Safety | 1 | 2009 | 1159 | 0.060 |
Why?
|
Biotechnology | 1 | 2006 | 283 | 0.060 |
Why?
|
Motivation | 1 | 2013 | 2020 | 0.050 |
Why?
|
Consensus | 2 | 2023 | 3211 | 0.050 |
Why?
|
Female | 13 | 2024 | 397187 | 0.050 |
Why?
|
Ions | 1 | 2003 | 256 | 0.050 |
Why?
|
Ethmoid Sinus | 1 | 2002 | 58 | 0.050 |
Why?
|
Internet | 1 | 2015 | 3110 | 0.050 |
Why?
|
Equipment Failure Analysis | 1 | 2005 | 845 | 0.050 |
Why?
|
Massachusetts | 1 | 2015 | 8890 | 0.050 |
Why?
|
Metals | 1 | 2007 | 713 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5953 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4754 | 0.050 |
Why?
|
Benchmarking | 1 | 2008 | 1057 | 0.050 |
Why?
|
Esophageal Neoplasms | 1 | 2011 | 1668 | 0.050 |
Why?
|
Radiography | 4 | 2012 | 6986 | 0.050 |
Why?
|
Brain Stem | 2 | 2012 | 859 | 0.050 |
Why?
|
Brain | 2 | 2024 | 27362 | 0.040 |
Why?
|
Spectrum Analysis | 1 | 2022 | 449 | 0.040 |
Why?
|
Spinal Cord | 2 | 2007 | 1812 | 0.040 |
Why?
|
Adenocarcinoma | 4 | 2003 | 6395 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10266 | 0.040 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2002 | 243 | 0.040 |
Why?
|
Medicine | 1 | 2008 | 945 | 0.040 |
Why?
|
Meningioma | 2 | 2007 | 1220 | 0.040 |
Why?
|
Carbon | 1 | 2003 | 672 | 0.040 |
Why?
|
Electronics | 1 | 2001 | 317 | 0.040 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 4978 | 0.040 |
Why?
|
Reference Standards | 1 | 2003 | 1014 | 0.040 |
Why?
|
Statistics as Topic | 1 | 2006 | 2357 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4598 | 0.040 |
Why?
|
Aged | 8 | 2018 | 171502 | 0.040 |
Why?
|
Online Systems | 1 | 2020 | 182 | 0.040 |
Why?
|
Accreditation | 1 | 2022 | 477 | 0.040 |
Why?
|
Biomedical Research | 1 | 2015 | 3463 | 0.040 |
Why?
|
Adult | 6 | 2018 | 223646 | 0.040 |
Why?
|
Middle Aged | 14 | 2018 | 223487 | 0.040 |
Why?
|
Pleural Neoplasms | 1 | 2003 | 612 | 0.040 |
Why?
|
Computer Systems | 2 | 2008 | 469 | 0.040 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
User-Computer Interface | 2 | 2008 | 1407 | 0.040 |
Why?
|
Health Facilities | 1 | 2022 | 577 | 0.040 |
Why?
|
Mesothelioma | 1 | 2003 | 811 | 0.040 |
Why?
|
Health Care Sector | 1 | 2019 | 196 | 0.040 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2666 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2018 | 313 | 0.030 |
Why?
|
Choroid Neoplasms | 1 | 1998 | 177 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 306 | 0.030 |
Why?
|
Neurilemmoma | 2 | 1999 | 522 | 0.030 |
Why?
|
Societies, Medical | 1 | 2008 | 3968 | 0.030 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 1997 | 137 | 0.030 |
Why?
|
Animals | 6 | 2024 | 169285 | 0.030 |
Why?
|
Tomography, Emission-Computed | 1 | 1999 | 1126 | 0.030 |
Why?
|
Prostate | 2 | 2022 | 1765 | 0.030 |
Why?
|
Dogs | 1 | 2020 | 3845 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2011 | 4310 | 0.030 |
Why?
|
Workflow | 1 | 2020 | 860 | 0.030 |
Why?
|
Urinary Bladder | 2 | 2007 | 1157 | 0.030 |
Why?
|
Biochemical Phenomena | 1 | 2015 | 59 | 0.030 |
Why?
|
Mathematical Computing | 1 | 1994 | 142 | 0.030 |
Why?
|
Bile Duct Neoplasms | 1 | 2000 | 614 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 1997 | 393 | 0.030 |
Why?
|
Background Radiation | 1 | 2013 | 2 | 0.030 |
Why?
|
Combined Modality Therapy | 3 | 2019 | 8542 | 0.030 |
Why?
|
Commerce | 1 | 2019 | 612 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2018 | 65379 | 0.030 |
Why?
|
Permeability | 1 | 2015 | 726 | 0.030 |
Why?
|
Models, Structural | 1 | 1993 | 340 | 0.030 |
Why?
|
Prostatectomy | 1 | 2021 | 1786 | 0.030 |
Why?
|
Splenic Neoplasms | 1 | 2003 | 97 | 0.030 |
Why?
|
Automation | 1 | 2014 | 589 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2022 | 2815 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2420 | 0.020 |
Why?
|
Pelvis | 1 | 1994 | 736 | 0.020 |
Why?
|
Rectal Neoplasms | 1 | 1998 | 1183 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2211 | 0.020 |
Why?
|
Rabbits | 1 | 2015 | 4773 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 2010 | 287 | 0.020 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2011 | 263 | 0.020 |
Why?
|
Sacrum | 1 | 2010 | 274 | 0.020 |
Why?
|
Anatomy, Regional | 1 | 2007 | 4 | 0.020 |
Why?
|
Work Simplification | 1 | 2007 | 8 | 0.020 |
Why?
|
Aged, 80 and over | 4 | 2018 | 59626 | 0.020 |
Why?
|
Pilot Projects | 2 | 2017 | 8741 | 0.020 |
Why?
|
Skull | 1 | 2012 | 829 | 0.020 |
Why?
|
Young Adult | 2 | 2013 | 60066 | 0.020 |
Why?
|
Neck | 1 | 1992 | 736 | 0.020 |
Why?
|
Curriculum | 1 | 2020 | 3782 | 0.020 |
Why?
|
Organ Specificity | 2 | 2003 | 1968 | 0.020 |
Why?
|
Models, Chemical | 1 | 2008 | 611 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4415 | 0.020 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2005 | 119 | 0.020 |
Why?
|
Surface Properties | 1 | 2008 | 1166 | 0.020 |
Why?
|
Neoplasm Staging | 3 | 2007 | 11244 | 0.010 |
Why?
|
Sample Size | 1 | 2007 | 846 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4648 | 0.010 |
Why?
|
Systems Integration | 1 | 2006 | 430 | 0.010 |
Why?
|
Maximum Allowable Concentration | 1 | 2003 | 64 | 0.010 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39354 | 0.010 |
Why?
|
Adolescent | 2 | 2010 | 89169 | 0.010 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2006 | 542 | 0.010 |
Why?
|
Treatment Failure | 1 | 2008 | 2661 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2003 | 4058 | 0.010 |
Why?
|
Physical Phenomena | 1 | 1999 | 48 | 0.010 |
Why?
|
United States | 2 | 2022 | 73039 | 0.010 |
Why?
|
Vascular Neoplasms | 1 | 2000 | 167 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 2006 | 1061 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2002 | 622 | 0.010 |
Why?
|
Microcomputers | 1 | 1998 | 139 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1652 | 0.010 |
Why?
|
Vena Cava, Inferior | 1 | 2000 | 463 | 0.010 |
Why?
|
Cisplatin | 1 | 2002 | 1660 | 0.010 |
Why?
|
Fundus Oculi | 1 | 1997 | 560 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2002 | 2914 | 0.010 |
Why?
|
Child, Preschool | 3 | 2008 | 42669 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2000 | 3620 | 0.010 |
Why?
|
Prospective Studies | 1 | 2016 | 54924 | 0.010 |
Why?
|
Fluorescein Angiography | 1 | 1997 | 1086 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2002 | 3474 | 0.010 |
Why?
|
Infant | 2 | 2008 | 36535 | 0.010 |
Why?
|
Child | 3 | 2008 | 80917 | 0.000 |
Why?
|
Posture | 1 | 1992 | 957 | 0.000 |
Why?
|
Kidney | 1 | 2000 | 7064 | 0.000 |
Why?
|
Liver | 1 | 2000 | 7578 | 0.000 |
Why?
|
Pneumonia | 1 | 1994 | 2163 | 0.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 11878 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2002 | 13677 | 0.000 |
Why?
|
Risk Factors | 1 | 2003 | 74944 | 0.000 |
Why?
|